A synthetic GHRH analog studied, and approved in a specific HIV lipodystrophy indication, for reducing visceral fat via endogenous GH release.
Pre-loaded with a typical Tesamorelin vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for Tesamorelin. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 2 mg | once daily | subcutaneous | Pivotal HIV lipodystrophy clinical trials (original 2 mg daily subcutaneous regimen) Phase 3 efficacy programs centered on 2 mg SC daily of the original formulation; newer branded presentations use bioequivalent adjusted nominal doses. Check current labeling when discussing approved product. |
| 1 mg – 2 mg | daily | subcutaneous | Research discussions of GH-axis body-composition protocols referencing the clinical dose anchor 1 mg vs 2 mg comparisons appeared in earlier development; 2 mg became the standard studied efficacious daily amount in pivotal work. |
People searching this page also look for: tesamorelin peptide dosage, tesamorelin peptide dosage chart, tesamorelin peptide dosage per day, tesamorelin peptide dosage for men, dosage for tesamorelin peptide, peptide tesamorelin dosage, tesamorelin dosage peptide, tesamorelin peptide dosage for fat loss.
Tesamorelin is a stabilized analog of growth hormone-releasing hormone that stimulates pituitary GH secretion, raising IGF-1 and influencing body composition. It is distinctive among research-discussed peptides because a specific formulation received FDA approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Phase 3 programs led by Falutz and colleagues demonstrated meaningful reductions in visceral adipose tissue over 26 weeks with daily subcutaneous administration, with extension data informing durability and metabolic secondary endpoints. Separate work evaluated liver fat and other cardiometabolic markers in HIV populations with central fat accumulation. These papers are the correct primary anchors for dosage education.
Outside labeled use, tesamorelin appears in broader body-composition research conversations. Educational content should keep approved indication, trial doses, and off-label speculation clearly separated, and should use research-use-only language for non-labeled contexts. This page summarizes documented ranges for reference by research professionals.
Tesamorelin binds pituitary GHRH receptors, amplifying physiologic GH pulsatility rather than supplying exogenous growth hormone directly. Increased GH acts on hepatic and peripheral tissues to raise IGF-1, promote lipolysis in visceral fat depots, and support lean-mass signals. Preferential VAT reduction with relative subcutaneous fat sparing was a recurring theme in HIV lipodystrophy trials. Downstream metabolic effects on triglycerides and hepatic fat have been examined as secondary physiology.
HIV-associated lipodystrophy · visceral adiposity · GH/IGF-1 axis · hepatic fat in endocrine research · body composition
Infectious-disease and endocrinology investigators working on HIV metabolic complications are the core clinical-research audience. Body-composition and NAFLD-oriented teams analyze VAT and liver-fat imaging endpoints. Peptide educators reference tesamorelin as a fully specified GHRH-analog case study with published phase 3 dose regimens.
Approved product labeling specifies controlled storage and reconstitution steps; research lyophilizates should remain refrigerated per COA. Use diluent only as directed, refrigerate reconstituted solution, and discard after the labeled period.
Clinical trials evaluate tesamorelin on optimized antiretroviral and lifestyle backgrounds, not stacked with other GH secretagogues. Combining GHRH analogs with GHRPs/ghrelin mimetics is sometimes hypothesized to amplify GH release but introduces confounding and safety-monitoring complexity. Research designs usually isolate the GHRH analog.
The questions people actually search for, answered plainly.
Pivotal HIV-associated lipodystrophy trials used 2 mg subcutaneously once daily for the original formulation. That is the best-documented human dose anchor in the peer-reviewed literature. Newer branded presentations may list different nominal milligram strengths that are designed to be exposure-matched, always read the specific label or trial protocol.
Follow the product's reconstitution instructions when using approved kits. For research lyophilized vials, choose a diluent volume that delivers 2 mg in a convenient syringe volume (for example, 2 mg in 1 mL yields 2 mg/mL). Do not assume multi-peptide blend volumes apply.
Daily dosing, not weekly, is the regimen used in the major VAT-reduction trials. Educational charts should show mcg or mg per day and note morning abdominal subcutaneous administration patterns described in clinical materials.
A simple chart maps 2 mg daily to syringe units at your concentration. If reconstituted to 2 mg/mL, 1.0 mL = 2 mg. IGF-1 monitoring schedules from clinical practice are separate from the injection-volume chart and belong in protocol documents.
Primary VAT imaging endpoints in phase 3 work were assessed at 26 weeks, with extension observations to 52 weeks in some analyses. Benefits on visceral fat were treatment-dependent in follow-up discussions. Timelines refer to trial populations with HIV-associated central fat accumulation.
As a peptide GHRH analog, plasma persistence is short; pharmacodynamic effects run through GH secretion and IGF-1 elevation lasting longer than the parent peptide's plasma spike. Cite clinical pharmacology references for numeric half-life values.
Evidence-based protocols study it as a single GH-axis agent. Stacking with CJC-1295, ipamorelin, or exogenous GH overlaps pathways and is not how pivotal trials were run. Research clarity favors monotherapy plus defined background care.
Primary literature on Tesamorelin. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides